Sapience Therapeutics
Sapience Therapeutics is a clinical-stage biotechnology company dedicated to eliminating hard-to-treat cancers through innovative peptide therapeutics, including SPEARs™ and SPARCs™. They focus on redefining druggability by targeting traditionally elusive oncogenic proteins, delivering precision therapy in oncology, and advancing cutting-edge platforms like ADAPT™ and PADS™. Their mission is to transform outcomes for patients with cancer by targeting what others have deemed unachievable.
Industries
Nr. of Employees
small (1-50)
Sapience Therapeutics
Tarrytown, New York, United States
Patents
Products
Lucicebtide (ST101)
An investigational therapeutic peptide developed to antagonize an intracellular oncogenic transcription factor; advanced in clinical development (Phase 2) for glioblastoma and other oncology indications with associated biomarker studies and regulatory interactions.
ST316
An investigational peptide antagonist of β‑catenin / Wnt signaling developed as a first-in-class approach to attenuate Wnt-dependent oncogenic activity; progressed through preclinical studies and into Phase 1/2 clinical evaluation.
FraAP Program
A discovery/development program in the company pipeline (listed as a distinct program in pipeline navigation).
ST101
ST101 is a first-in-class antagonist of C/EBPβ currently being evaluated in Phase 1-2 clinical studies for advanced unresectable and metastatic solid tumors, including breast cancer, GBM, metastatic cutaneous melanoma, and castration-resistant prostate cancer.
SPEARs™ (Stabilized Peptides Engineered Against Regulation)
Therapeutic peptides designed to target transcription factors, key drivers of oncogenesis and immune suppression, with precision and effectiveness. These peptides penetrate cell membranes, modulate protein-protein interactions, are well tolerated, and non-immunogenic.
PADS (Peptide Antagonist Discovery System)
A peptide antagonist discovery system that uses a library-based protein fragment complementation screen in an intracellular environment to identify peptide hits resistant to degradation and target-specific for further development.
Lucicebtide (ST101)
An investigational therapeutic peptide developed to antagonize an intracellular oncogenic transcription factor; advanced in clinical development (Phase 2) for glioblastoma and other oncology indications with associated biomarker studies and regulatory interactions.
ST316
An investigational peptide antagonist of β‑catenin / Wnt signaling developed as a first-in-class approach to attenuate Wnt-dependent oncogenic activity; progressed through preclinical studies and into Phase 1/2 clinical evaluation.
FraAP Program
A discovery/development program in the company pipeline (listed as a distinct program in pipeline navigation).
ST101
ST101 is a first-in-class antagonist of C/EBPβ currently being evaluated in Phase 1-2 clinical studies for advanced unresectable and metastatic solid tumors, including breast cancer, GBM, metastatic cutaneous melanoma, and castration-resistant prostate cancer.
SPEARs™ (Stabilized Peptides Engineered Against Regulation)
Therapeutic peptides designed to target transcription factors, key drivers of oncogenesis and immune suppression, with precision and effectiveness. These peptides penetrate cell membranes, modulate protein-protein interactions, are well tolerated, and non-immunogenic.
PADS (Peptide Antagonist Discovery System)
A peptide antagonist discovery system that uses a library-based protein fragment complementation screen in an intracellular environment to identify peptide hits resistant to degradation and target-specific for further development.
Expertise Areas
- Peptide therapeutics
- Protein-protein interaction drug discovery
- Oncology clinical development (Phase I/II)
- Biomarker discovery and translational research
Key Technologies
- Peptide library screening
- Peptide stabilization and optimization
- Intracellular targeting of protein-protein interactions
- β-catenin / Wnt pathway modulation